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g/kg intravenous glucose tolerance test (IVGTT), and Si was calculated 
according to Bergman’s Minimal Model. 
Results: At baseline, we observed an inverse correlation between Si and 
fasting plasma insulin (r = -0.44, p < O.OOl), BMI (r = -0.42, P = 0.002). 
plasma mate (r = -0.42, P = 0.002), plasma triglycerides (r = -0.34, p = 
0.01) and fasting plasma glucose levels (r = -0.29, P = 0.03). Furthermore, 
a positive correlation between Si and plasma HDL cholesterol levels (r = 
0.39, P = 0.03) and maximal oxygen uptake (r = 0.35, P = 0.009) was 
found. The Si did not correlate with NYHA class, W/H ratio, age, EF, 
or plasma catecholamine levels. A trend towards an inverse correlation 
between insulin sensitivity and plasma endothelin was seen (r = -0.26, P 
= 0.056). Si was unchanged both within the carvedilol group from 2.63 & 
1.45 to 2.38 f 1.64 * 10-4 * mm-l/mU * L-l (NS) and compared with 
the placebo group (-0.25 vs. -0.33 * 10-4 * min-l/mU * L-l, NS). 
Conclusion: Additional treatment with carvedilol to patients with mild 
to moderate CHF is neutral with regard to influence insulin sensitivity. 
Further prospective studies may show how selective beta-blockers affect 
the insulin sensitivity in patients with CHF. 
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In the Randomized ALdactone Evaluation Study @ALES), spironolactone, 
an aldosterone-receptor antagonist, decreased mortality and morbidity in 
patients with severe congestive heart failure. To clarify the mechanism 
of action, the effects of spironolactone (25 mg daily) on the plasma 
concentration of N-terminal proatrial natriuretic factor (N-p&&IF) and of 
brain natriuretic peptide (BNP), a nemohormonal marker of left ventricular 
function, were assessed in a subset of 107 patients (NYHA III-IV, mean 
EF:25%) at entry (TO) into study, at 3 months (T3) and at 6 months 
(T6) and compared the changes to the placebo group. 54 patients were 
included in the spironolactone group and 53 in the placebo group. Data 
were compared using a Student t-test on a logtransformed scale and the 
natriuretic peptides changes from baseline are expressed by the ratios 
T3mO and T6fTO. Compared to the placebo group, a significant decrease 
of 19% in N-proANF was observed at 3 months in the spironolactone 
group (1 .O vs 0.81, p = 0.03). Moreover, we evidenced overtime, com- 
pared to the placebo group, a significant 23% reduction of BNP plasma 
concentration in the spironolactone group (0.99 vs 0.77, p = 0.004 and 
0.96 vs 0.77, p = 0.05, respectively at 3 and 6 months). In conclusion, 
spironolactone significantly decreased the plasma levels of N-proANF and 
more importantly of BNP. The reduction of BNP plasma levels during the 
follow-up period reflects the beneficial effects of spironolactone on the 
left ventricular remodeling through the reduction of myocardial stretching. 
Spironolactone can influence the progression of left ventricular remodeling 
by several mechanisms: reduction in wall stress, reduction in interstitial 
fibrosis, and reorganization of the collagen matrix. This neuroendocrine 
modulation and cardioprotection may contribute to limit the progression of 
heart failure and to explain the decreased mortality and morbidity observed 
with spironolactone. 
P52/10423 Vltamln C acutely improves ejection duration in 
chronic heart faihwe (CHF) oatients in a heart rate 
independent fashion _ 
M. Schmitt, A.K. Nightingale, G.R. Ellis, J. Morris-Thurgood, 
A. Broadley, J.R. Cockcroft, M.P. Frenneaux. Cardiology, Heart Research 
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Background: Shortened ejection duration (ED) is a feature of chronic 
heart failure (CHF) and correlates with stroke work index and fractional 
shortening and is inversely related to pulmonary capillary wedge pressure. 
ED is determined both by intrinsic myocardial function and also by the 
effects of the reflected aortic pressure wave. Increased pulse wave velocity 
(PWV) due to increased large artery stiffness results in earlier return of 
the pressure wave and may contribute to early aortic valve closure. We 
hypothesized that by improving endothelial function and reducing PWV, 
vitamin C would prolong ED in patients with CHF. 
Methods: 40 CHF patients with an ejection fraction (EF) of less than 
35% (21 NYHA II and 19 NYHA III) were studied. Pulse wave analysis 
(PWA) was performed with the SphygmoCor@ (PWV Medical) device 
which uses a high fidelity tonometer to record a radial pressure trace from 
which central aortic pressures and ED can be accurately estimated applying 
a generalized transfer factor. ED measurements have been validated against 
invasive recordings. Baseline recordings were performed after 10 minutes 
of supine rest. 30 patients were randomised in a double blind parallel group 
fashion to receive either 2 g vitamin C or N-Saline i.v. PWA was performed 
30 minutes later. 
Results: Data are expressed as mean & SEM. ED was 282 f 5 msec at 
baseline and was shorter in NYHA III vs NYHA II patients (ED 271 + 8 
msec vs 290 f 4 msec; p = 0.03). Vitamin C prolonged ejection duration 
from 284 f 5 msec to 298 f 6 msec: p = 0.0005 vs baseline, p = 0.018 
vs placebo. When ED was cormcted for heart rate (HR) these changes 
remained very significant; p = 0.008 vs baseline, p = 0.007 vs placebo. 
Conclusions: 1. In CHF ejection duration is reduced in parallel with 
the reduction in functional capacity (NYHA class). Vitamin C given 
intravenously prolongs ED. This might theoretically be due to either a 
myocardial effect or a delay in wave reflection as a result of improved large 
artery endothelial function. 3. PWA can be used to determine accurately the 
effects of pharmacological interventions on ventricular-vascular coupling. 
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HMG-CoA Reductase Inhibitors (statins) are used infrequently in patients 
with heart failure and systolic left ventricular dysfunction in part due to 
concerns about ubiquinone (co-enzyme Q) inhibition, mitochondrial dys- 
function, and associated myopathy. We examined the effects of statins on 
clinical outcomes (mortality) in the Losartan Heart Failure Survival Study, 
ELITE II, a multinational, double-blind, randomized study of patients > 
60 years with symptomatic heart failure which showed that the AI1 blocker 
losartan had no significant difference in mortality compared to the ACE 
inhibitor, captopril. 
Methods: A retrospective analysis of outcomes from the ELITE 11 
study was performed to compare the effects of statins on mortality (Cox 
regression with B-blocker use at randomization as stratification factor, and 
region as covariate). 
Results: Of the 3,152 patients enrolled in ELITE II, 359 (I 1%) patients 
were on statins at the time of randomization and 617 (19.6%) administered 
concomitantly with study therapy. Baseline demographics were generally 
similar between patients on statins compared to those not on statins except 
for distribution in NYHA class (62% YS 50% class II respectively), history 
of ischemic heart disease (91% vs 77%) and myocardial infarction (78% 
YS 56%). Regardless of treatment with losartan or captopril there was a 
significantly lower mortality rate for patients on statins at randomization, 
and similarly, for patients on statins after randomization. No significant 
difference was seen in this effect between losartan and captopril. 
With Stains’ Without Statins 
N Crude Rate (%) N Crude Rate (‘5) 
Totals 359 38 (10.6) 2193 492(17.6) 
Losartan 176 ZO(l1.4) 1402 260(18.5) 
Captopril 183 18 (9.8) 1391 232 (16.7) 
L&Cap. A (95% CI) 1.19 (0.63.2.26) 1.12 (0.94, 1.34) 
‘p = 0.003 for statin effect on reducing mortality across treatment groups (Cox regression) 
Conclusion: In this study patients with symptomatic heart failure and 
left ventricular dysfunction, patients who took statins had significantly 
lower mortality; losartan was not different from captopril in reducing 
mortality either with or without statins as concomitant therapy. Prospective 
evaluation of statin use in patients with heart failure is warranted. 
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G. Shafiyan, M.J. Zeebaeenejad, M. Ghassemi. Cardiology & Arryfhmia, 
Hazrat Fatemeh Heart Center, Shiraz, Iran 
Introduction: ACE inhibitors are using progressively as antihypertensive 
drugs and also in the management of patients with congestive Heart failure. 
